On July 22, Zixin Pharmaceutical announced that “the company intends to sign the “Investment Framework Agreement†with Nabsys2.0, through the initial capital increase of US$6 million or equivalent, up to US$36 million or equivalent investment in RMB. A total of $42 million or equivalent in RMB, and ultimately a 67% stake in Nabsys 2.0.
According to the information, Nabsys 2.0 is a limited liability company registered in Delaware, USA, and the legal representative is Barrett Bready. Nabsys 2.0 is a research-based innovation company that combines the development, production, sales, expertise and advanced equipment of the fourth generation of DNA analysis systems with strong basic research and applied scientific research knowledge and experience. DNA analysis received the "1000 Genome" award from the National Institute of Human Genome Research, National Institutes of Health. The fourth-generation DNA analysis system developed by Nabsys 2.0 integrates pure solid-state, microelectronics, single-molecule sequencing analysis and advanced technologies in multiple fields to significantly exceed the resolution of optical methods for long-chain DNA molecules and the entire genome. The electronic map was analyzed. The accuracy of the gene fragment sequence, the precise location of the fragment in the genome, and the analysis of a wide range of genomic structural variation are achieved, and the entire genome information is obtained.
For this investment, Zixin Pharmaceutical said, "At the same time that the company's genetic sequencer technology has been industrialized, the company intends to acquire Nabsys 2.0 and understand and be familiar with the chief experts in the field of genetic sequencers and their foundations. The clinical application perspective, access to the operation and rules of international innovation projects, and the full and effective combination of the company's genetic sequencer technology and the fourth-generation DNA analysis system will help the company's genetic sequencer technology to develop and complement in the future, and promote the company's new generation. The research and development of the genetic sequencer is a step forward for the internationalization of the company's research and development. At the same time, the company's investment in Nabsys 2.0 is one of the important measures to implement the international development strategy, which is conducive to accelerating the company's internationalization strategy in the field of genetic sequencers. The pace of the company lays the foundation for the company to achieve its international strategic goals, strengthens the exchange and cooperation between the company and the international market, expands the US market and the global market. Accelerates the international operation of the company's brand, production, talents and technology, enhances the brand image, and further Enhance the company's core competitiveness."
According to the 2015 financial report of Zixin Pharmaceutical, Zixin Pharmaceutical is mainly engaged in the research, development, production and sales of proprietary Chinese medicines and ginseng products. The research, development, production and sales of genetic sequencers are currently under development, 2015 8 In the month, Zixin Pharmaceutical's Zhongji Zixin BIGIS second-generation sequencer was officially launched, and with China Inspection and Quarantine Research Institute, Peking University People's Hospital, Beijing Entry-Exit Inspection and Quarantine Bureau, Ocean University of China, China University of Traditional Chinese Medicine, etc. The customer signed a trial agreement. In July 2016, Zixin Pharmaceutical stated that its base for mass production of genetic sequencers has settled in Beijing and is currently in the stage of mass production.
According to reports, the BIGIS gene sequencer is jointly developed by the Institute of Genomics and Semiconductors of the Chinese Academy of Sciences. It is a highly integrated next-generation sequencing platform that integrates a series of electromechanical control, microfluidics, optical and software control systems. The sequencing of the BIGIS sequencer is long. For 100~1000bp, the sequencing throughput is 5~400Mb, and the accuracy is up to 99.995%. The system provides a full range of sequencing solutions, including: whole genome sequencing, especially microbial genomes such as bacteria and viruses, targeted region resequencing, digital expression profiling, etc.; can be widely used in the identification and genetic diagnosis of infectious diseases, Genetic disease genetic diagnosis and screening, tumor and blood disease genetic testing and individualized diagnosis and treatment, inspection and quarantine, and pharmacogenomics and other health and disease-related fields. The BIGIS sequencer has a refined appearance, and the equipment price is lower than 1/3 of the imported equipment, and the application cost is lower than 1/5 of the imported equipment. Strong and competitive in the relevant market.
It is reported that with the continuous maturity of the gene sequencer business, in the future, Zixin Pharmaceutical will form the business structure and development pattern of the three core businesses of proprietary Chinese medicine, ginseng products and gene sequencer.
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.full-pharma.com